Engineered virus takes on cancer in first human trial

NCT ID NCT06171178

Terminated Disease control Sponsor: Astellas Pharma Global Development, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase trial tested ASP1012, a virus engineered to infect and kill cancer cells while making them visible to the immune system. It was given alone or with the immunotherapy pembrolizumab to 15 adults with advanced solid tumors. The main goals were to check safety and find the right dose for future studies.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: ASP1012 (an oncolytic virus) and pembrolizumab
What this could lead to: If it works, this could point toward a new treatment option for advanced solid tumors that have not responded to standard therapies.
What could go wrong: This is a very early, first-in-human phase 1 trial with only 15 participants, so safety and effectiveness are not yet known. The trial was terminated, which may indicate challenges.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

colorectal cancer gastric cancer melanoma ovarian cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SOLID TUMOR

Contacts and locations

Locations

Emory Winship Cancer Institute

Atlanta, Georgia, 30322, United States
Gabrail Cancer and Research Center

Canton, Ohio, 44718, United States
Hoag Memorial Hospital Presbyterian

Newport Beach, California, 92663, United States
Karmanos Cancer Institute

Detroit, Michigan, 48201, United States
Mary Crowley Cancer Research

Dallas, Texas, 75230, United States
Roswell Park Cancer Institute

Buffalo, New York, 14263, United States
The Angeles Clinic and Research Institute

Los Angeles, California, 90025, United States
University of Iowa Hospitals

Iowa City, Iowa, 52242, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.